AtCor signs $800K contract expansion
AtCor Medical (ASX:ACG) has expanded an existing contract to supply its SphygmoCor diagnostic to the tune of $800,000.
Following its recent announcement of a 1H13 profit, AtCor Medical has now added a further $800,000 to its expected revenues following the signing of a contract expansion to an existing customer.
AtCor will supply SphygmoCor to a major pharmaceutical company to support clinical trials in North and South America, Europe and Asia.
SphygmoCor is the company’s device for measuring central aortic blood pressures and arterial stiffness non-invasively.
“We are delighted to have secured this expansion contract,” said AtCor Medical CEO Duncan Ross.
“The non-invasive measurement of central blood pressure and arterial stiffness is particularly important for drug development, which requires accurate, insightful data to fully understand the efficacy of new drugs.”
AtCor (ASX:ACG) was up 1% at 10c in light trading as of around 11 am Monday morning.
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
